ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue519,601492,660401,480
Cost of Revenue108,10992,93180,615
Gross Profit411,492399,729320,865
Operating Expenses
Research Development203,437149,20973,470
Selling General and Administrative244,037216,530204,013
Non Recurring--6,991
Total Operating Expenses---
Operating Income or Loss-35,98233,99036,391
Income from Continuing Operations
Total Other Income/Expenses Net10,241851906
Earnings Before Interest and Taxes-25,74134,84137,297
Interest Expense16,52715,4729,288
Income Before Tax-42,26819,36928,009
Income Tax Expense-6,6658,31110,337
Minority Interest---
Net Income From Continuing Ops-34,61811,05817,672
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-34,61811,05817,672
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-34,61811,05817,672